Zanidatamab (zani) in previously treated HER2+biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study Meeting Abstract
| Authors: | Pant, S.; Fan, J.; Oh, D.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla, T.; Xie, F.; Metges, J. P.; Ying, J. E.; Bridgewater, J. A.; Tejani, M. A.; Chen, E. Y. S.; Wasan, H. S.; Ducreux, M. P.; Ma, J. F.; Garfin, P. M.; Harding, J. J. |
| Abstract Title: | Zanidatamab (zani) in previously treated HER2+biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500116 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.450 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 450 -- Source: Wos |
